Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans

Michael P. Gotsbacher, Sungmin Cho, Ho Jeong Kwon, Peter Karuso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Daptomycin is a recently introduced, last-resort antibiotic that displays a unique mode of action against Gram-positive bacteria that is not fully understood. Several bacterial targets have been proposed but no human binding partner is known. Methods: In the present study we tested daptomycin in cell viability and proliferation assays against six human cell lines, describe the synthesis of biotinylated and fluorescently labeled analogues of daptomycin. Biotinylated daptomycin was used as bait to isolate the human binding partner by the application of reverse chemical proteomics using T7 phage display of five human tumor cDNA libraries. The interaction between the rescued protein and daptomycin was validated via siRNA knockdown, DARTS assay and immunocytochemistry. Results: We have found that daptomycin possesses selective growth inhibition of some cancer cell lines, especially MCF7. The unbiased interrogation of human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of daptomycin; ribosomal protein S19. Using a drug affinity responsive target stability (DARTS) assay in vitro, we show that daptomycin stabilizes RPS19 toward pronase. Fluorescently labeled daptomycin stained specific structures in HeLa cells and co-localized with a RPS19 antibody. Conclusion: This study provides, for the first time, a human protein target of daptomycin and identifies RPS19 as a possible anticancer drug target for the development of new pharmacological applications and research.

Original languageEnglish
Article number16
JournalProteome Science
Volume15
Issue number1
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Daptomycin
Anti-Bacterial Agents
Bacteriophage T7
Assays
Bacteriophages
Cells
Gene Library
ribosomal protein S19
Pharmaceutical Preparations
Cell Line
Pronase
Gram-Positive Bacteria
HeLa Cells
Proteomics
Small Interfering RNA
Tumors
Neoplasms
Cell Survival
Bacteria
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology

Cite this

Gotsbacher, Michael P. ; Cho, Sungmin ; Kwon, Ho Jeong ; Karuso, Peter. / Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. In: Proteome Science. 2017 ; Vol. 15, No. 1.
@article{3182d73665784f088cf8a827365a6b0c,
title = "Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans",
abstract = "Background: Daptomycin is a recently introduced, last-resort antibiotic that displays a unique mode of action against Gram-positive bacteria that is not fully understood. Several bacterial targets have been proposed but no human binding partner is known. Methods: In the present study we tested daptomycin in cell viability and proliferation assays against six human cell lines, describe the synthesis of biotinylated and fluorescently labeled analogues of daptomycin. Biotinylated daptomycin was used as bait to isolate the human binding partner by the application of reverse chemical proteomics using T7 phage display of five human tumor cDNA libraries. The interaction between the rescued protein and daptomycin was validated via siRNA knockdown, DARTS assay and immunocytochemistry. Results: We have found that daptomycin possesses selective growth inhibition of some cancer cell lines, especially MCF7. The unbiased interrogation of human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of daptomycin; ribosomal protein S19. Using a drug affinity responsive target stability (DARTS) assay in vitro, we show that daptomycin stabilizes RPS19 toward pronase. Fluorescently labeled daptomycin stained specific structures in HeLa cells and co-localized with a RPS19 antibody. Conclusion: This study provides, for the first time, a human protein target of daptomycin and identifies RPS19 as a possible anticancer drug target for the development of new pharmacological applications and research.",
author = "Gotsbacher, {Michael P.} and Sungmin Cho and Kwon, {Ho Jeong} and Peter Karuso",
year = "2017",
month = "7",
day = "1",
doi = "10.1186/s12953-017-0124-2",
language = "English",
volume = "15",
journal = "Proteome Science",
issn = "1477-5956",
publisher = "BioMed Central",
number = "1",

}

Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. / Gotsbacher, Michael P.; Cho, Sungmin; Kwon, Ho Jeong; Karuso, Peter.

In: Proteome Science, Vol. 15, No. 1, 16, 01.07.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans

AU - Gotsbacher, Michael P.

AU - Cho, Sungmin

AU - Kwon, Ho Jeong

AU - Karuso, Peter

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: Daptomycin is a recently introduced, last-resort antibiotic that displays a unique mode of action against Gram-positive bacteria that is not fully understood. Several bacterial targets have been proposed but no human binding partner is known. Methods: In the present study we tested daptomycin in cell viability and proliferation assays against six human cell lines, describe the synthesis of biotinylated and fluorescently labeled analogues of daptomycin. Biotinylated daptomycin was used as bait to isolate the human binding partner by the application of reverse chemical proteomics using T7 phage display of five human tumor cDNA libraries. The interaction between the rescued protein and daptomycin was validated via siRNA knockdown, DARTS assay and immunocytochemistry. Results: We have found that daptomycin possesses selective growth inhibition of some cancer cell lines, especially MCF7. The unbiased interrogation of human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of daptomycin; ribosomal protein S19. Using a drug affinity responsive target stability (DARTS) assay in vitro, we show that daptomycin stabilizes RPS19 toward pronase. Fluorescently labeled daptomycin stained specific structures in HeLa cells and co-localized with a RPS19 antibody. Conclusion: This study provides, for the first time, a human protein target of daptomycin and identifies RPS19 as a possible anticancer drug target for the development of new pharmacological applications and research.

AB - Background: Daptomycin is a recently introduced, last-resort antibiotic that displays a unique mode of action against Gram-positive bacteria that is not fully understood. Several bacterial targets have been proposed but no human binding partner is known. Methods: In the present study we tested daptomycin in cell viability and proliferation assays against six human cell lines, describe the synthesis of biotinylated and fluorescently labeled analogues of daptomycin. Biotinylated daptomycin was used as bait to isolate the human binding partner by the application of reverse chemical proteomics using T7 phage display of five human tumor cDNA libraries. The interaction between the rescued protein and daptomycin was validated via siRNA knockdown, DARTS assay and immunocytochemistry. Results: We have found that daptomycin possesses selective growth inhibition of some cancer cell lines, especially MCF7. The unbiased interrogation of human cDNA libraries, displayed on bacteriophage T7, revealed a single human target of daptomycin; ribosomal protein S19. Using a drug affinity responsive target stability (DARTS) assay in vitro, we show that daptomycin stabilizes RPS19 toward pronase. Fluorescently labeled daptomycin stained specific structures in HeLa cells and co-localized with a RPS19 antibody. Conclusion: This study provides, for the first time, a human protein target of daptomycin and identifies RPS19 as a possible anticancer drug target for the development of new pharmacological applications and research.

UR - http://www.scopus.com/inward/record.url?scp=85021643000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021643000&partnerID=8YFLogxK

U2 - 10.1186/s12953-017-0124-2

DO - 10.1186/s12953-017-0124-2

M3 - Article

VL - 15

JO - Proteome Science

JF - Proteome Science

SN - 1477-5956

IS - 1

M1 - 16

ER -